

Severe Lung Infection and Septicemia Caused by *Paludibacterium purpuratum*—A Case Report and Evaluation of Bacterial Traits

Cong-Tat Cia,^{1,2} Jenn-Wei Chen,³ Shu-Li Su,¹ Pei-Fang Tsai,⁴ Cing-Ying Shu,³ Wen-Chien Ko,^{1,2} and Po Lin Chen^{1,2,3}

¹Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ²Infection Control Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ³Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, and ⁴Department of Pathology, National Cheng Kung University Hospital, Tainan, Taiwan

Paludibacterium species are gram stain–negative rods that are facultatively anaerobic; they have been isolated from wetland soil. Clinical infection caused by this genus is rarely reported. We report the case of an 84-year-old woman with chronic renal disease and hypertension who acquired *P. purpuratum* lung infection and septicemia in Southern Taiwan.

Keywords. drug resistance; *Paludibacterium purpuratum*; pneumonia; septicemia.

CASE REPORT

An 84-year-old woman with chronic kidney disease, hypertension, mild cognitive dysfunction, and a uterine mass who lived in the rural area of Tainan City presented to a regional hospital due to fever, dry cough, and dyspnea for 2 days, just after a 10-day heavy rain with total precipitation >800 mm. Chest x-ray showed bilateral lower lung patches and pleural effusion (Figure 1). She had septic shock, acute kidney injury, and respiratory failure on admission and received antibiotics, fluid resuscitation, and tracheal intubation. She was transferred to a tertiary hospital and admitted to the intensive care unit.

Curved gram-negative bacteria were isolated from blood culture (Figure 2A). Direct gram stain of the pleural fluid demonstrated curved gram-negative bacilli (Figure 2B). The biochemical phenotype of the isolate was oxidase-positive, catalase-negative, urease-negative, and glucose-nonfermenting.

VITEK MS (bioMérieux, Marcy l’Etoile, France) failed to identify the bacterium, and the VITEK2 GN ID card (bioMérieux, Durham, NC, USA) reported *Burkholderia mallei* with 90% probability. The diagnosis of infection caused by *Paludibacterium* species was made by 16S rRNA polymerase chain reaction (PCR) assay. Primers 11F (5′-GTTTGATCCTGGCTCAG-3′) and 1512R (5′-GGYTACCTTGTACG ACTT-3′), as previously described [1], were used to amplify the conserved 16S rRNA genes. The 1.5-kb amplified fragments from blood and pleural effusion cultures were identified as *Paludibacterium purpuratum*, with corresponding 99.3% and 98.9% similarity by comparing the sequences deposited in the GenBank database (accession No. LC633506, type strain *Paludibacterium purpuratum* THUN1379). While the pleural effusion culture did not yield any bacteria, 16S rRNA sequencing for the inoculated broth identified the existence of *P. purpuratum*.

Her pneumonia and empyema responded well to ampicillin-sulbactam and bilateral pleural drainage with 24-Fr chest tubes. She was extubated 4 days after admission, and her acute kidney injury resolved later. She was discharged home 20 days later and is presently doing well.

Analyses of 16S rRNA gene sequences showed that the clinical *P. purpuratum* blood isolate (defined as strain B53371) shared the highest sequence similarity with *P. purpuratum* KJ031 (99.6%), followed by *P. yongneupense* NBRC 106427 (98.3%) and *P. paludis* KBP-21 (98.2%). Whole-genome sequencing of the *P. purpuratum* strain B53371 was performed with the PacBio Sequencing Platform (PACBIO, Menlo Park, CA, USA). The assemblies reported here were deposited at DDBJ/EMBL/GenBank under accession No. CP069163. The genome size for the *P. purpuratum* strain B53371 is 3.63 M (Supplementary Figure 1). Morphology, drug susceptibility, and metabolic abilities were assayed for the *P. purpuratum* B53371 strain.

The *P. purpuratum* isolate was able to grow on blood agar plate and chocolate agar plates at 35°C. Gram stain showed curved and long gram-negative bacilli. The indole test for *P. purpuratum* isolate was negative, and the hanging drop motility test showed a negative result. The isolate grew less at 42°C than that at 35°C. It did not grow on MacConkey plate or colistin nalidixic acid blood agar plate. The appearance of colony morphology on blood agar plate was small and gray at 24 hours and became smooth, translucent, or white at 48 hours (Figure 3A). The colonies on chocolate agar plate showed a white or translucent appearance at 48 hours (Figure 3B). The isolated strain showed low minimal inhibitory concentration (MIC) levels for ampicillin/sulbactam, piperacillin/tazobactam, cefotaxime, cefepime, fluoroquinolones, meropenem, and aminoglycosides, but a high MIC level for colistin in vitro (Table 1). As there are no

Received 2 July 2021; editorial decision 28 September 2021; accepted 30 September 2021; published online 5 October 2021.

Correspondence: Po-Lin Chen, MD, PhD, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan (cplnmay@gmail.com).

Open Forum Infectious Diseases® 2021

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com <https://doi.org/10.1093/ofid/ofab501>



Figure 1. Chest x-ray on admission showed bilateral lung patches and pleural effusions.

available criteria for the MIC of antibiotics of *Paludibacterium* species, the break points of MICs for *Acinetobacter* species and other non-*Enterobacteriaceae* are provided as references [2].

Phenotype microarray plates were used to analyze the metabolic profiles of the *P. purpuratum* strain. We analyzed whether the strain was able to ferment carbon, nitrogen, phosphorus, and sulfur substrates using the MicroPlate assay according to previous research [3]. Briefly, the strain was grown for 2 days on LB agar at 25°C. The cells were inoculated into IF-0a medium (Biolog, Inc., CA, USA) to achieve 42% transmittance measured with a spectrophotometer (Novaspec II; Pharmacia Biotech). This suspension was added to an IF-0a medium-containing tetrazolium (Dye Mix A; Biolog, Inc., CA, USA) in a 1:5 ratio to produce a cell suspension with a final transmittance of 85%. Then, 100 μ L of this cell suspension was transferred to each well of Biolog plates PM1 and PM2A (Biolog, Inc.). A solution containing 2 M of sodium succinate and 200 M of ferric citrate was added to the remaining suspension in a 1:100 ratio. Then, 100 μ L of this suspension was transferred to each well of Biolog plates PM3B and PM4A (Biolog, Inc., CA, USA). The plates were read with a spectrophotometer (Varioskan Flash; Thermo Fisher Scientific, MA, USA) at 590 and 750 nm. The A_{750} value was subtracted from the A_{590} value to reduce the background absorbance unrelated to the




Figure 2. Gram stain of colonies after subculture from the positive blood culture bottles revealed curved gram-negative bacillus, which was identified as *Paludibacterium purpuratum* later (A). Gram stain of empyema showed numerous polymorphonuclear neutrophil infiltrations and phagocytosis of a gram-negative pathogen (arrowhead) (B).




Figure 3. The colony morphology of the blood isolate *Paludibacterium purpuratum* strain B53371 on (A) blood agar plate and (B) chocolate agar after growth for 48 hours at 35°C.

Table 1. Criteria of Minimal Inhibitory Concentrations for the Clinical *Paludibacterium purpuratum* Strain B53371

<i>P. purpuratum</i> Strain B53371	MICs, µg/mL	Interpretive Categories and MIC Break Points for <i>Acinetobacteria</i> Species			Interpretive Categories and MIC Break Points for Other Non- <i>Enterobacteriaceae</i>		
		S	I	R	S	I	R
		Penicillin	32				≤16
Ampicillin/sulbactam	8/4	≤8/4	16/8	≥32/16			
Amoxicillin/clavulanate	16						
Piperacillin/tazobactam	≤4	≤16	32–64	≥128	≤16	32–64	≥128
Cefotaxime	≤1	≤8	16–32	≥64	≤8	16–32	≥64
Cefepime	≤1	≤8	16	≥32	≤8	16	≥32
Meropenem	1	≤2	4	≥8	≤4	8	≥16
Amikacin	≤2	≤16	32	≥64	≤16	32	≥64
Gentamicin	≤1	≤4	8	≥16	≤4	8	≥16
Ciprofloxacin	≤0.25	≤1	2	≥4	≤1	2	≥4
Levofloxacin	≤0.12	≤2	4	≥8	≤2	5	≥8
Colistin	8	≤2		≥4			

MICs for penicillin and amoxicillin/clavulanate were determined by Etest (bioMérieux, Marcy l’Etoile, France). The other drugs were measured by VITEK 2 AST N322 card (bioMérieux, Marcy l’Etoile, France).

Abbreviation: MIC, minimum inhibitory concentration.

Table 2. Metabolizing Abilities of the Clinical *Paludibacterium purpuratum* Strain B53371

<i>P. purpuratum</i> Strain B53371		
Carbon sources	N-acetyl-D-glucosamine	+
	L-proline	+
	L-aspartic acid	+
	D-gluconic acid	+
	L-glutamic acid	+
	D-fructose	+
	α-D-glucose	+
	L-asparagine	+
	D-glucose-1-phosphate	+
	b-methyl-D-glucoside	+
	Glycyl-L-aspartic acid	+
	Inosine	+
	Propionic acid	+
	L-serine	+
	L-alanyl-glycine	+
	Methyl pyruvate	+
	D-fructose-6-phosphate	+
Nitrogen sources	Hydroxy-L-proline	+
	L-arginine, L-ornithine	+
	L-asparagine	+
	L-aspartic acid	+
	N-acetyl-D-glucosamine	+
	L-glutamic acid	+
	L-serine, D-glucosamine	+
	Adenosine	+
	Guanosine	+
	Ala-Gln	+
Ala-Glu	+	
Ala-Gly	+	
Ala-Thr	+	
Gly-Asn	+	
Gly-Gln	+	
D-glucose-6-phosphate	+	

reduced redox dye, based on the manufacturer’s instructions. Values >0.2 were considered positive, and values <0.2 were considered negative. Of the 596 test substrates, the test strain could utilize 33 substrates, mainly carbon- and nitrogen-containing sources. The results are summarized in [Table 2](#).

DISCUSSIONS

Paludibacterium species are gram-stain negative rods that are facultatively anaerobic; they have been isolated from environments in Japan, South Korea, China, and Taiwan [4–8]. In a metagenomic study surveying subgingival microbiota in Taiwanese patients, *Paludibacterium* was one of the genera comprising subgingival microbiota among healthy individuals in contrast to patients with chronic periodontitis [9]. The study conducted by Tsai et al. in Taiwan did not analyze *Paludibacter* at the genus level. In addition, reports of invasive infection caused by *Paludibacterium* species are also scarce. The present case might have acquired infection through inhalation of pathogens stirred by heavy rainfall, similar to melioidosis.

P. purpuratum could be misidentified by the VITEK2 GN ID card (bioMérieux, Durham, NC, USA) diagnostic system. The probability for *Burkholderia mallei* was only 90% in the present report. Although *P. purpuratum* and *B. mallei* share similar morphology features on blood agar and chocolate plates, most clinical microbiological laboratories could differentiate them from each other by several tests: (1) *B. mallei* can grow on a MacConkey plate, but not *P. purpuratum*. (2) *P. purpuratum* is a long, curved, and motile gram-negative bacillus, distinct from *B. mallei* in morphology, showing a small, nonmotile gram-negative bacillus [10].

Cultivation of this facultatively anaerobic *Paludibacterium* is susceptible to an array of antibiotics in vitro except for colistin. Whole-genome sequencing analysis revealed that the *P. purpuratum* isolate carried *ICR-Mo*, a chromosomally encoded determinant of colistin resistance. *ICR-Mo*, which is close to the *mcr-1/2* polymyxin resistance gene, encodes an enzyme that helps to modify lipid A by transferring phosphoethanolamine moiety from its donor phosphatidylethanolamine to the 1'-(or 4')-phosphate position of lipid A. Expression of *ICR-Mo* in bacteria may prevent the formation of reactive oxygen species induced by colistin [11]. The present case recovered well with ampicillin/sulbactam therapy. In conclusion, we herein reported the first invasive *P. purpuratum* infection in Taiwan. Infection in susceptible hosts might happen due to exposure or inhalation of this pathogen accidentally.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We are grateful to the Diagnostic Microbiology and Antimicrobial Resistance Laboratory, National Cheng Kung University Hospital, for providing the technical services of bacteria culture, phenotype microplate assay, and drug susceptibility testing.

Financial support. This study was supported by National Cheng Kung University Hospital (NCKUH-110040027), Ministry of Science and Technology (MOST 108-2628-B-006-012).

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of

Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. C.T.C. and P.L.C. contributed to study conception, design, paper writing, and analysis. J.W.C. contributed to data analysis. S.L.S., P.F.T., and C.Y.S. contributed to experiments. W.C.K. contributed to finalizing the manuscript.

Patient consent. The patient agreed with the publication in case report form and signed the informed consent. The study was approved by the ethical committee of our hospital (IRB No. A-EC-110-33).

References

1. Relman DA. Universal bacterial 16S rRNA amplification and sequencing. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. *Diagnostic Molecular Microbiology: Principles and Applications*. ASM Press; 1993:489–95.
2. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing*, M100. 30th ed. Wayne PA: CLSI; 2020.
3. Zboralski A, Biessy A, Savoie MC, et al. Metabolic and genomic traits of phytobeneficial phenazine-producing *Pseudomonas* spp. are linked to *Rhizosphere* colonization in *Arabidopsis thaliana* and *Solanum tuberosum*. *Appl Environ Microbiol* 2020; 86:e02443–19.
4. Ueki A, Akasaka H, Suzuki D, Ueki K. *Paludibacter propionicigenes* gen. nov., sp. nov., a novel strictly anaerobic, gram-negative, propionate-producing bacterium isolated from plant residue in irrigated rice-field soil in Japan. *Int J Syst Evol Microbiol* 2006; 56:39–44.
5. Kwon SW, Kim BY, Kim WG, et al. *Paludibacterium yongneupense* gen. nov., sp. nov., isolated from a wetland, Yongneup, in Korea. *Int J Syst Evol Microbiol* 2008; 58:190–4.
6. Kang H, Kim H, Joung Y, et al. *Paludibacterium purpuratum* sp. nov., isolated from wetland soil. *Int J Syst Evol Microbiol* 2016; 66:2711–6.
7. Qiu YL, Kuang XZ, Shi XS, et al. *Paludibacter jiangxiensis* sp. nov., a strictly anaerobic, propionate-producing bacterium isolated from rice paddy field. *Arch Microbiol* 2014; 196:149–55.
8. Sheu SY, Chen ZH, Young CC, Chen WM. *Paludibacterium paludis* sp. nov., isolated from a marsh. *Int J Syst Evol Microbiol* 2014; 64:2497–502.
9. Tsai CY, Tang CY, Tan TS, et al. Subgingival microbiota in individuals with severe chronic periodontitis. *J Microbiol Immunol Infect* 2018; 51:226–34.
10. Jorgensen JH, Carroll KC, Funke G, et al. *Miscellaneous gram-negative bacteria*. In: *Manual of Clinical Microbiology*. 11th ed. ASM Press; 2015.
11. Wei W, Srinivas S, Lin J, et al. Defining *ICR-Mo*, an intrinsic colistin resistance determinant from *Moraxella osloensis*. *PLoS Genet* 2018; 14:e1007389.